1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Analytical Tool - Hematological Cancers

"Analytical Tool – Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.

Included in this advantageous package are three products already appreciated by many of our customers:

A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Hematological Cancers Drug Pipeline Update 2014*

The Package Includes:
- A progress analysis on current and emerging drugs
- Information on most companies active in R&D
- Information on key industry related projects
- Data from most important clinical trials
- Information on early developmental stage projects
- Possibility of performing advanced searches suited to your individual needs

This Tool will Assist You in:
- Tracking cutting edge companies, therapies and new technologies
- Rapid identification of partners & competitors
- Laying down a comprehensive framework for further analysis of the field
- Producing presentations surrounding the development of hematological cancer therapeutics
- Identifying emerging products & key areas of pharmaceutical R&D

*This software application is a searchable database reflects the most recent advances in the field of hematological cancer drug development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker's software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeeker’s software applications give better overview, specific search capabilities and great dynamic reports.

Table Of Contents

Analytical Tool - Hematological Cancers

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Hematological Cancers - Highly Innovative Pipeline Continues Trend towards Targeted, Patient-Specific Therapies

Frontier Pharma: Hematological Cancers - Highly Innovative Pipeline Continues Trend towards Targeted, Patient-Specific Therapies

  • $ 6 995
  • Industry report
  • June 2016
  • by GBI Research

Frontier Pharma: Hematological Cancers - Highly Innovative Pipeline Continues Trend towards Targeted, Patient-Specific Therapies Summary Hematological malignancies are a class of cancer that affect the ...

Chronic myeloid leukemia

Chronic myeloid leukemia

  • $ 5 000
  • Industry report
  • May 2016
  • by Datamonitor Healthcare

Sprycel and Tasigna continue to compete for market share in second-line CML as generic imatinib begins to supersede Gleevec in all markets. This report addresses the following questions: - What are the ...

Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.) - Pipeline Review, H1 2016

Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.) - Pipeline Review, H1 2016

  • $ 3 500
  • Industry report
  • June 2016
  • by Global Markets Direct

Lysine-Specific Histone Demethylase 1A (Lysine (K)-Specific Demethylase 1 or Flavin-Containing Amine Oxidase Domain-Containing Protein 2 or EC 1.) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ...


Download Unlimited Documents from Trusted Public Sources

Vaccine Industry in China

  • August 2016
    10 pages
  • Vaccine  

    HPV Vaccine  

    Cervical Cancer  

  • China  

    United States  

    Asia  

View report >

Cancer Statistics in the UK

  • August 2016
    4 pages
  • Cancer  

  • United Kingdom  

View report >

Ovarian Cancer Statistics in the US - Forecast

  • August 2016
    2 pages
  • Ovarian Cancer  

    Therapy  

  • United States  

View report >

Related Market Segments :

Leukemia

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.